- Raw materials
- Antibacterials
- Rufloxacin
Rufloxacin API Manufacturers & Suppliers
0 verified results
All Rufloxacin data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Rufloxacin | CAS No: 101363-10-4 | GMP-certified suppliers
A medication that provides broad-spectrum antibacterial activity for systemic infections, with enzyme inhibition properties and potential effects on cardiac QTc intervals.
Therapeutic categories
Product Snapshot
- Rufloxacin is available as oral tablets in various coated and film-coated formulations
- It is primarily developed for antimicrobial therapy
- Rufloxacin currently holds experimental status and is not approved by major regulatory agencies
Clinical Overview
Pharmacologically, rufloxacin functions within the fluoroquinolone class, which is known to inhibit bacterial DNA synthesis by targeting topoisomerase II enzymes, including DNA gyrase and topoisomerase IV. These targets are essential for bacterial DNA replication, transcription, and repair. Though precise mechanistic data for rufloxacin are not extensively documented, its classification as a topoisomerase II inhibitor aligns with the general mode of action observed in related fluoroquinolones. Rufloxacin also acts as an inhibitor of the cytochrome P450 enzyme CYP1A2, which may influence the metabolism of co-administered drugs metabolized by this pathway.
While detailed absorption, distribution, metabolism, and excretion (ADME) parameters for rufloxacin are not publicly specified, fluoroquinolones typically exhibit good oral bioavailability, wide tissue distribution, hepatic metabolism, and renal excretion of both parent compounds and metabolites.
Safety considerations for rufloxacin include its potential to prolong cardiac QTc intervals, a class effect seen in fluoroquinolones that requires cautious evaluation in clinical development to mitigate the risk of arrhythmias. As an experimental agent, comprehensive toxicity and safety profiles have not been fully established.
Rufloxacin is not commercially marketed under any notable brand names and remains primarily of interest in research contexts. For pharmaceutical formulation scientists, sourcing rufloxacin as an active pharmaceutical ingredient (API) demands rigorous quality control to ensure chemical purity and stability, given the sensitivity of fluoroquinolones to photodegradation and potential for impurity formation. Compliance with relevant pharmacopeial standards and regulatory guidelines is essential to support further developmental and investigational use.
Identification & chemistry
| Generic name | Rufloxacin |
|---|---|
| Molecule type | Small molecule |
| CAS | 101363-10-4 |
| UNII | Y521XM2900 |
| DrugBank ID | DB13772 |
Formulation & handling
- Rufloxacin is a small molecule quinoline carboxylic acid primarily formulated for oral administration as tablets, including coated and film-coated variants.
- The compound exhibits moderate water solubility and low lipophilicity (LogP 0.3), which should be considered during formulation for optimal bioavailability.
- Stability data is limited; appropriate handling conditions and protective packaging may be necessary to preserve formulation integrity.
Regulatory status
Rufloxacin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
